India
· Delayed Price · Currency is INR Ajanta Pharma Statistics
Total Valuation
Ajanta Pharma has a market cap or net worth of INR 328.98 billion. The enterprise value is 323.30 billion.
| Market Cap | 328.98B |
| Enterprise Value | 323.30B |
Important Dates
The next estimated earnings date is Tuesday, July 29, 2025.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | Nov 6, 2024 |
Share Statistics
Ajanta Pharma has 124.89 million shares outstanding. The number of shares has decreased by -0.66% in one year.
| Current Share Class | 124.89M |
| Shares Outstanding | 124.89M |
| Shares Change (YoY) | -0.66% |
| Shares Change (QoQ) | -0.32% |
| Owned by Insiders (%) | 42.33% |
| Owned by Institutions (%) | 19.98% |
| Float | 41.84M |
Valuation Ratios
The trailing PE ratio is 35.82 and the forward PE ratio is 31.25. Ajanta Pharma's PEG ratio is 2.79.
| PE Ratio | 35.82 |
| Forward PE | 31.25 |
| PS Ratio | 7.08 |
| PB Ratio | 8.68 |
| P/TBV Ratio | 8.79 |
| P/FCF Ratio | 39.20 |
| P/OCF Ratio | 28.43 |
| PEG Ratio | 2.79 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 25.49, with an EV/FCF ratio of 38.52.
| EV / Earnings | 35.13 |
| EV / Sales | 6.96 |
| EV / EBITDA | 25.49 |
| EV / EBIT | 28.76 |
| EV / FCF | 38.52 |
Financial Position
The company has a current ratio of 2.85, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.85 |
| Quick Ratio | 1.80 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.04 |
| Debt / FCF | 0.06 |
| Interest Coverage | 54.23 |
Financial Efficiency
Return on equity (ROE) is 25.02% and return on invested capital (ROIC) is 18.88%.
| Return on Equity (ROE) | 25.02% |
| Return on Assets (ROA) | 14.56% |
| Return on Invested Capital (ROIC) | 18.88% |
| Return on Capital Employed (ROCE) | 27.97% |
| Revenue Per Employee | 5.76M |
| Profits Per Employee | 1.14M |
| Employee Count | 8,073 |
| Asset Turnover | 0.96 |
| Inventory Turnover | 1.24 |
Taxes
In the past 12 months, Ajanta Pharma has paid 2.69 billion in taxes.
| Income Tax | 2.69B |
| Effective Tax Rate | 22.60% |
Stock Price Statistics
The stock price has increased by +9.79% in the last 52 weeks. The beta is 0.24, so Ajanta Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | +9.79% |
| 50-Day Moving Average | 2,599.15 |
| 200-Day Moving Average | 2,840.05 |
| Relative Strength Index (RSI) | 53.20 |
| Average Volume (20 Days) | 108,296 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ajanta Pharma had revenue of INR 46.48 billion and earned 9.20 billion in profits. Earnings per share was 73.53.
| Revenue | 46.48B |
| Gross Profit | 35.77B |
| Operating Income | 11.24B |
| Pretax Income | 11.89B |
| Net Income | 9.20B |
| EBITDA | 12.68B |
| EBIT | 11.24B |
| Earnings Per Share (EPS) | 73.53 |
Balance Sheet
The company has 6.15 billion in cash and 474.20 million in debt, giving a net cash position of 5.68 billion or 45.44 per share.
| Cash & Cash Equivalents | 6.15B |
| Total Debt | 474.20M |
| Net Cash | 5.68B |
| Net Cash Per Share | 45.44 |
| Equity (Book Value) | 37.90B |
| Book Value Per Share | 303.53 |
| Working Capital | 18.47B |
Cash Flow
In the last 12 months, operating cash flow was 11.57 billion and capital expenditures -3.18 billion, giving a free cash flow of 8.39 billion.
| Operating Cash Flow | 11.57B |
| Capital Expenditures | -3.18B |
| Free Cash Flow | 8.39B |
| FCF Per Share | 67.21 |
Margins
Gross margin is 76.96%, with operating and profit margins of 24.19% and 19.80%.
| Gross Margin | 76.96% |
| Operating Margin | 24.19% |
| Pretax Margin | 25.58% |
| Profit Margin | 19.80% |
| EBITDA Margin | 27.29% |
| EBIT Margin | 24.19% |
| FCF Margin | 18.06% |
Dividends & Yields
This stock pays an annual dividend of 56.00, which amounts to a dividend yield of 2.05%.
| Dividend Per Share | 56.00 |
| Dividend Yield | 2.05% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 3 |
| Payout Ratio | 37.96% |
| Buyback Yield | 0.66% |
| Shareholder Yield | 2.71% |
| Earnings Yield | 2.80% |
| FCF Yield | 2.55% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 22, 2022. It was a forward split with a ratio of 1.5.
| Last Split Date | Jun 22, 2022 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |